



202 Maplewood Avenue • Ronceverte, West Virginia 24970

Phone (304) 647-4411 • Facsimile (304) 647-6010 • www.gvmc.com

May 27, 2014

USNRC – Region I
2100 Renaissance Blvd, Suite 100
King of Prussia, PA 19406-2713


Re: License Number 47-17199-01

To Whom It May Concern:

Please amend our radioactive material license as follows:

1. Add Jillian L. Douglas, D.O. as an authorized user for materials identified in 10 CFR 35.100 and oral administration of sodium iodide iodine-131. Dr. Douglass is identified an authorized user on the NRC license for Cabell Huntington Hospital License # 47-00404-02. A copy of this document is attached.

Thank you for your attention to this matter.


Administrator

584056
NMSS/RGNI MATERIALS-002

Official Use Only - Security-Related Information

NRC FORM 374

PAGE 1 OF 6 PAGES

Amendment No. 56

Duplicate

U.S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE

Duplicate

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Cabell Huntington Hospital 2. 1340 Hal Greer Boulevard Huntington, West Virginia 25701-0195		In accordance with the letters dated January 17, 2014 and February 5, 2014, 3. License number 47-00404-02 is amended in its entirety to read as follows: 4. Expiration date January 31, 2024 5. Docket No. 030-03370 Reference No.	
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Iridium 192 permitted by 10 CFR 35.600 E. Yttrium 90 F. Americium 241	7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (Varian Medical Systems Haan GmbH Model GammaMed 232) E. Resin microspheres (Sirtex Medical Limited Model SIR-Spheres® [manufactured by Sirtex Wilmington LLC, Sirtex Medical Limited, or ANSTO Radiopharmaceuticals and Industrials]) F. Sealed Source (Amersham International Plc Model AMC.24)	8. Maximum amount that licensee may possess at any one time under this license A. As needed B. As needed C. 1500 millicuries D. 2 sources, 1 source not to exceed 12 curies and 1 source not to exceed 9 curies E. 189 millicuries per vial and 1000 millicuries total F. 14 millicuries	
9. Authorized use: A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100. B. Any imaging and localization study permitted by 10 CFR 35.200.			

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

PAGE 2 OF 6 PAGES

Duplicate

Duplicate

Duplicate

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-00404-02

Docket or Reference Number
030-03370

Amendment No. 56

- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
- D. One source for medical use permitted by 10 CFR 35.600, in a Varian Medical Systems Haan GmbH Model GammaMed Plus remote afterloader unit. The source activity may not exceed 10 curies at the time of medical use. One source in its shipping container as necessary for replacement of the source in the remote afterloader unit.
- E. For permanent brachytherapy in the Sirtex Medical Limited SIR-Spheres® delivery system.
- F. For storage only pending disposal.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 1340 Hal Greer Boulevard, Huntington, West Virginia and 1400 Hal Greer Boulevard, Huntington, West Virginia.
- 11. The Radiation Safety Officer for this license is James T. Norweck, M.S., DABR.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
 - B. Physicians permitted to work as authorized users for Yttrium 90-SIR-Spheres® in accordance with the notification commitments in the letter dated January 17, 2014.
 - C. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Paul D. Akers, M.D.

35.100; 35.200; 35.300

Mark J. Akers, M.D.

35.100; 35.200

Marsha S. Anderson, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for imaging and localization studies

Rodger A. Blake, M.D.

35.100; 35.200; 35.300

Paul H. Blom, M.D.

35.100; 35.200, Yttrium-90 SIR-Spheres®

Peter A. Chirico, M.D.

35.100; 35.200; 35.300

James A. Cochrane, M.D.

35.100; 35.200; 35.300

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

PAGE 3 OF 6 PAGES

Duplicate

Duplicate

Duplicate

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

47-00404-02

Docket or Reference Number

030-03370

Amendment No. 56

Authorized Users

Material and Use

Ricky J. Compton, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for imaging and localization studies

Jeremy F. Cuda, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131

Robert J. Cure, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131

Jillian L. Douglas, D.O.

35.100; oral administration of sodium iodide iodine-131

Hans G. Dransfeld, M.D.

35.100; 35.200; 35.300

Joseph W. Dransfeld, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for imaging and localization studies

Ayman Elkadry, M.D.

35.100; oral administration of sodium iodide iodine-131

Andrew B. Freeman, M.D.

Oral administration of sodium iodide iodine-131; Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required; Iridium 192 for uses in a High Dose Rate Remote Afterloader.

Joshua Dale Gibson, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131

Lee C. Haikal, M.D.

35.100; 35.200; 35.300

Michael V. Korona, Jr., M.D.

35.100; 35.200, Yttrium-90 SIR-Spheres®

Eric L. Leonard, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for imaging and localization studies

Duplicate

Donald R. Lewis, M.D.

Duplicate

35.100; 35.200; 35.300

Duplicate

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

PAGE 4 OF 6 PAGES

Duplicate

Duplicate

Duplicate

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-00404-02

Docket or Reference Number
030-03370

Amendment No. 56

Authorized Users

Grant D. Petty, M.D.

Material and Use

35.100; 35.200

James M. Reynolds, M.D.

35.100; 35.200, Yttrium-90 SIR-Spheres®

Charles M. Siegler, M.D.

35.100; 35.200

Ralph A. Stevens, M.D.

35.100; 35.200

Torin P. Walters, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for imaging and localization studies

James K. Watson, M.D.

35.100; 35.200

Gabriel M. Werder, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131

D. The following individuals are authorized medical physicists as indicated:

Authorized Medical Physicists

Material and Use

C. Thomas Brannan, M.S., DABR

Iridium 192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training

Joseph Britt Colenda, M.S., DABR

Iridium 192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training

James G. Cutlip, M.S.

Iridium 192 in a High Dose Rate Remote Afterloader Unit for calibrations, spot-checks, and training

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

PAGE 5 OF 6 PAGES

Duplicate

Duplicate

Duplicate

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
47-00404-02Docket or Reference Number
030-03370

Amendment No. 56

16. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
17. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:
- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months or at the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.
 - B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
 - C. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
 - D. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
 - E. Tests for leakage and/or contamination, limited to leak test sample collection, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services. The licensee is not authorized to perform the analysis; analysis of leak test samples must be performed by persons specifically licensed by U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
 - F. Records of leak test results shall be kept in units of microcuries and shall be maintained for 5 years.

Duplicate

Duplicate

Duplicate

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

PAGE 6 OF 6 PAGES

Duplicate

Duplicate

Duplicate

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License Number
47-00404-02

Docket or Reference Number
030-03370

Amendment No. 56

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and the letter dated January 17, 2014. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- | | | |
|----|---------------------------------|---------------|
| A. | Application dated July 29, 2013 | [ML13217A406] |
| B. | Letter dated December 27, 2013 | [ML14036A182] |
| C. | Letter dated January 17, 2014 | [ML14036A166] |



For the U.S. Nuclear Regulatory Commission

Date March 12, 2014

By

Original signed by Penny Lanzisera

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406

Duplicate

Duplicate

Duplicate

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information



NUCLEAR REGULATORY COMMISSION

REGION I
2100 RENAISSANCE BOULEVARD, SUITE 100
KING OF PRUSSIA, PA 19406-2713

March 12, 2014

Docket No. 03003370
Control No. 582954

License No. 47-00404-02

Tim Martin, MBA, RT(R), ARRT, ASRT, ACHE
Vice President of Ancillary and Support Services
Cabell Huntington Hospital
1340 Hal Greer Boulevard
Huntington, WV 25701

SUBJECT: CABELL HUNTINGTON HOSPITAL, LICENSE AMENDMENT, CONTROL NO. 582954

Dear Mr. Martin:

This refers to your license amendment requests dated January 17, 2014 and February 5, 2014. Enclosed with this letter is the amended license adding Joshua Dale Gibson, M.D., Ayman Elkadry, M.D., and Jillian L. Douglas, D.O., as Authorized Users, and removing Aamir Hussian, M.D. from the license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Med, Ind, & Academic Uses**; then **Licensee Toolkits**, see our **toolkit index page**. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

The NRC's Safety Culture Policy Statement became effective in June 2011. While a policy statement and not a regulation, it sets forth the agency's *expectations* for individuals and organizations to establish and maintain a positive safety culture. You can access the policy statement and supporting material that may benefit your organization on NRC's safety culture Web site at <http://www.nrc.gov/about-nrc/regulatory/enforcement/safety-culture.html>. We strongly encourage you to review this material and adapt it to your particular needs in order to develop and maintain a positive safety culture as you engage in NRC-regulated activities.

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

T. Martin

2

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 56

cc:

~~James T. Norweck, M.S., DABR, Radiation Safety Officer~~

Official Use Only - Security-Related Information

This is to acknowledge the receipt of your letter application dated

05/27/2014, and to inform you that the initial processing which includes an administrative review has been performed.

47-17199-01 (Amendment)
☒ There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 584056.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI)
(6-96)

Sincerely,
Licensing Assistance Team Leader